Feature / NICE update

NICE UPDATE

NICE published the following guidance in June:

Clinical guidance

• CG 161 Falls – A costing statement has been produced for this guideline. The new inpatient section of the guideline is unlikely to have a significant cost impact for the NHS, as most components of multifactorial assessment and intervention (assessing mobility and continence) are already standard practice.
• CG162 Stroke rehabilitation – The annual cost to commissioners associated with implementing this guidance is anticipated to be significant and is estimated at £37,000 per 100,000 population. Commissioners are also asked to review clinical psychology services and services to nursing and care home at a local level.
• CG 163 The diagnosis and management of idiopathic pulmonary fibrosis – Improved awareness of idiopathic pulmonary fibrosis will lead to an earlier and more accurate diagnosis, with a resultant improvement in disease management and improved quality of life for patients. Costs for a standard interstitial lung disease network population of 1.5 million is estimated to be about £40,000.
• CG 164 Familial breast cancer (update) – The annual change in resource use arising from implementing the recommendations considered in the costing analysis is estimated at a cost of £4,900 per 100,000 population.

Technology guidance

• TA 287 Costing report: Rivaroxaban for treating pulmonary embolism and the prevention of recurrent venous thromboembolism – Annual costs are estimated at around £18,800 for a population of 100,000 based on the standard assumptions in the model at year five following implementation.
• TA 289 Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis – The guidance is unlikely to result in a significant change in resource use in the NHS as it is not recommended
• TA290 Mirabegron for treating symptoms of overactive bladder – The annual cost per 100,000 population is estimated as £40,800

Public health guidance

• PH 45 tobacco harm reduction – This costing report is relevant to organisations with responsibility for commissioning stop smoking services. Because the tobacco harm reduction recommendations are intended to support and extend the reach and impact of existing stop smoking services, it is expected that implementing this guidance would increase the number of people accessing services. Costs to be considered locally are highlighted in the report.

NICE update was prepared by Stephen Brookfield, senior costing analyst at NICE